SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-20-317638
Filing Date
2020-12-15
Accepted
2020-12-15 09:26:30
Documents
12
Effectiveness Date
2020-12-15

Document Format Files

Seq Description Document Type Size
1 DEFM14A d87012ddefm14a.htm DEFM14A 2266472
2 GRAPHIC g87012g01h45.jpg GRAPHIC 23568
3 GRAPHIC g87012g05k45.jpg GRAPHIC 24082
4 GRAPHIC g87012g08j45.jpg GRAPHIC 25664
5 GRAPHIC g87012g09h74.jpg GRAPHIC 26115
6 GRAPHIC g87012g10n10.jpg GRAPHIC 24624
7 GRAPHIC g87012g13s60.jpg GRAPHIC 25070
8 GRAPHIC g87012g60k45.jpg GRAPHIC 37518
9 GRAPHIC g87012g77o31.jpg GRAPHIC 15422
10 GRAPHIC g87012g90m50.jpg GRAPHIC 32243
11 GRAPHIC g87012img22.jpg GRAPHIC 6332
12 GRAPHIC g87012img33.jpg GRAPHIC 1669
  Complete submission text file 0001193125-20-317638.txt   2577994
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-38959 | Film No.: 201388343
SIC: 2834 Pharmaceutical Preparations